Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

NCT05924672 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

2

Enrollment

OTHER

Sponsor class

Conditions

Castration-Resistant Prostate Carcinoma
Metastatic Malignant Neoplasm in the Bone
Stage IVB Prostate Cancer AJCC v8

Interventions

DRUG: Radium-223
PROCEDURE: PSMA Positron Emission Tomography (PET) Scan
DRUG: Technetium Tc 99M Medronate

Sponsor

University of California, San Francisco

Collaborators

[object Object]